Our valuation and moat rating aren't affected by this company's decision.
Necessity means dividends are very secure for drugmakers.
We continue to view the wide-moat company as fairly valued, with the market appropriately appreciating the heavy patent losses over the next five years.
We continue to view this wide-moat stock as undervalued and maintain our fair value estimate.
The wide-moat firm faces market headwinds, but we anticipate its outlook will reverse in 2021.
We expect J&J to lead the charge in developing a coronavirus vaccine and view the stock as slightly overvalued.
Moats, valuations, and dividends look attractive in the market pullback.
Drug manufacturers are the most undervalued industry in the sector.
Fears of a progressive president and changes to the healthcare system have faded.
Our base case calls for a strong economic rebound in 2021 following a recession in 2020.
Biden's nomination would reduce the likelihood of significant drug pricing policy changes, which is in line with our expectations.
We see some opportunity for investment, especially in Merck.
An ESG frame helps us bring a better look at valuation within the healthcare sector.
We plan to maintain our fair value estimate for the wide-moat firm, which offered solid 2020 guidance.
We have raised our fair value estimate based on an improving outlook.
Results for the wide-moat firm were slightly below expectations due to marketing expenditures.
We expect the strong 2020 guidance to support a slight increase to our fair value estimate, but we still don’t expect the stock to look undervalued.
We don't expect a major overhaul of the U.S. healthcare system.
The narrow-moat firm is undervalued and well-positioned with its dividend.
Recent results from some of the most undervalued large drugmakers we cover.
We don't see any major impact to our fair value estimate based on the quarter's outperformance.
We see opportunities in providers, managed care, drugs, and biotech.
Check out these pharmaceutical stocks for both capital appreciation and dividend yield.
The $572 million payment amount for Johnson & Johnson is lower than expected, and the wide-moat firm plans to appeal the case.
The divestment of the generics business should strengthen Pfizer's competitive positioning.
Sector director Damien Conover shares his key takeaways from Johnson & Johnson, Novartis, Glaxo, and Bristol Myers Squibb's reports.
We're finding some opportunity in a sector that's fairly valued overall.
The first-quarter performance reinforces our wide moat rating.
We expect solid results but will be listening for what a reduction in rebating means for sales growth at various firms, among other trends.
Even with the recent glyphosate loss, scientific studies still support the product.
Drug manufacturers and healthcare providers offer the most upside.
Both Bristol-Myers Squibb and Pfizer are well-positioned for growth.
The continued strong data in multiple cancers reinforces the strength of Keytruda across multiple indications.
The wide-moat firm's core drug distribution business posted gains of 6% in results that were largely in line with expectations.
The wide-moat drugmaker's lower than expected 2019 guidance doesn't dent our view that the firm will be bolstered by an improving pipeline.
We continue to view the stock as undervalued after total sales matched expectations.
Earnings were mostly in line with our expectations, and we're maintaining our fair value estimate.
The wide-moat firm was leg by its drug unit, but increasing generic pressures weigh on the 2019 outlook.
We don't expect any major changes to our fair value estimate based on the deal, with the expected revenue from acquired cancer drugs offsetting the purchase price and increased R&D expenditures.
We expect appeals to delay any impact but revoking the ACA would likely create the most pressure for the healthcare services companies.
We think the pullback in the stock puts the shares near our fair value estimate and think the long-term implications on the price will not be significant after litigation.
While we believe the restructuring makes strategic sense, the related one-time costs are higher than we expected.
The sale of noncore consumer assets should allow the firm to focus on other consumer products while the purchase of Tesaro improves its standing in the PARP oncology setting.
Damien Conover expects to see fewer major changes to U.S. healthcare policy, and he offers some picks for investors.
Pfizer won't be able to access the U.S. market with its biosimilar version until late 2023, providing AbbVie with additional years of exclusivity and strong cash flows.
The wide-moat firm's results were better than consensus, and we view the stock as slightly overvalued.
We view the company as slightly overvalued but don't expect any major changes to our fair value estimate.
Cost-saving plans and product launches should offset patent losses and drive growth.
We think that Albert Bourla will continue the wide-moat firm's current strategic focus.
A focus on unmet medical needs is helping pharma firms maintain their competitive advantage.